Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies
Public ClinicalTrials.gov record NCT04001517. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (DLB)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled, proof-of-principle study of neflamapimod versus matching placebo (randomized 1:1) administered with food for 16 weeks in subjects with DLB. The primary objective is to evaluate the effect of neflamapimod on cognitive function as assessed in a study-specific Cogstate Neuropsychological Test Battery (NTB). Secondary endpoints include the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB), Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI-10), Timed Up and Go Test, and electroencephalogram (EEG) as a potential biomarker for DLB.
Study identification
- NCT ID
- NCT04001517
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 91 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 55 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2019
- Primary completion
- Jun 29, 2020
- Completion
- Jun 29, 2020
- Last update posted
- Jun 28, 2023
2019 – 2020
United States locations
- U.S. sites
- 22
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Diego (UCSD) | La Jolla | California | 92037 | — |
| Pacific Neuroscience Institute | Santa Monica | California | 90404 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Elite Clinical Research | Miami | Florida | 33144 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66103 | — |
| Massachusetts General Hospital | Charlestown | Massachusetts | 02129 | — |
| University of Michigan | Ann Arbor | Michigan | 48105 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Cleveland Clinic - Lou Ruvo Center for Brain Health | Las Vegas | Nevada | 89106 | — |
| New York Presbyterian Hospital - Columbia University Medical Center | New York | New York | 10032 | — |
| University of Rochester | Rochester | New York | 14618 | — |
| University of North Carolina | Chapel Hill | North Carolina | 27599 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| The Ohio State University | Columbus | Ohio | 43210 | — |
| Summit Research Network | Portland | Oregon | 97210 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| University of Virginia | Charlottesville | Virginia | 22908 | — |
| National Clinical Research, Inc. | Richmond | Virginia | 23294 | — |
| Northwest Clinical Research Center | Bellevue | Washington | 98007 | — |
| University of Washington | Seattle | Washington | 98104 | — |
| Inland Northwest Research | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04001517, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 28, 2023 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04001517 live on ClinicalTrials.gov.